Catharine C Bulik

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 4

Top Topics

Hodgkin Lymphoma

Locally Advanced

Oxidative Stress

Drug Administration

Top Venues

Clinical cancer research : an official journal of the American Association for Cancer Research

This page only lists publications with an associated author ORCID identifier.

Publications

William F Maguire, Daniel Lee, Chana Weinstock, Xin Gao, Catharine C Bulik, Sundeep Agrawal, Elaine Chang, Salaheldin S Hamed, Erik W Bloomquist, Shenghui Tang, Richard Pazdur, Paul G Kluetz, Laleh Amiri-Kordestani, Daniel L Suzman
FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (10) (2024)
William F Maguire, Daniel Lee, Chana Weinstock, Xin Gao, Catharine C Bulik, Sundeep Agrawal, Elaine Chang, Salaheldin S Hamed, Erik W Bloomquist, Shenghui Tang, Richard Pazdur, Paul G Kluetz, Laleh Amiri-Kordestani, Daniel L Suzman
FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (10) (2024)
William F Maguire, Daniel Lee, Chana Weinstock, Xin Gao, Catharine C Bulik, Sundeep Agrawal, Elaine Chang, Salaheldin S Hamed, Erik W Bloomquist, Shenghui Tang, Richard Pazdur, Paul G Kluetz, Laleh Amiri-Kordestani, Daniel L Suzman
FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (10) (2024)
William F Maguire, Daniel Lee, Chana Weinstock, Xin Gao, Catharine C Bulik, Sundeep Agrawal, Elaine Chang, Salaheldin S Hamed, Erik W Bloomquist, Shenghui Tang, Richard Pazdur, Paul G Kluetz, Laleh Amiri-Kordestani, Daniel L Suzman
FDA Approval Summary: Enfortumab Vedotin Plus Pembrolizumab for Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)